Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.92 is 77% above its 5-year average of -3.94, near the high end of its 5-year range (-7.16–-0.92).
55.12% above its 12-month average of -2.05.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:23:14.380Z. Historical observations retain their original dates. Historical series through 2016-09-09.
EARNINGS PER SHARE (EPS)
-0.92
EARNINGS PER SHARE (EPS) AVG TTM
-2.05
EARNINGS PER SHARE (EPS) AVG 3Y
-3.17
EARNINGS PER SHARE (EPS) AVG 5Y
-3.94
EARNINGS PER SHARE (EPS) AVG 10Y
-3.09
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+55.12%
CURRENT VS 3Y AVG
+70.98%
CURRENT VS 5Y AVG
+76.66%
CURRENT VS 10Y AVG
+70.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Relmada Therapeutics, Inc.
Market Cap
$344.04M
Earnings Per Share (EPS)
-0.92
TTM Avg
-2.05
3Y Avg
-3.17
5Y Avg
-3.94
Market Cap
$346.73M
Earnings Per Share (EPS)
-0.29
TTM Avg
-0.18
3Y Avg
-0.18
5Y Avg
-0.18
Market Cap
$349.70M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.39
3Y Avg
-1.39
5Y Avg
-0.93
Market Cap
$352.67M
Earnings Per Share (EPS)
-0.25
TTM Avg
-0.22
3Y Avg
-0.27
5Y Avg
-0.28
Market Cap
$353.00M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$353.88M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$355.36M
Earnings Per Share (EPS)
0.36
TTM Avg
0.33
3Y Avg
0.27
5Y Avg
0.36
Market Cap
$355.43M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
Market Cap
$330.19M
Earnings Per Share (EPS)
-1.18
TTM Avg
-0.80
3Y Avg
-0.80
5Y Avg
-0.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $344.04M | -0.92 | -2.05 | -3.17 | -3.94 |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -0.29 | -0.18 | -0.18 | -0.18 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -0.99 | -1.39 | -1.39 | -0.93 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | -0.25 | -0.22 | -0.27 | -0.28 |
| Embecta Corp. (EMBC)vs › | $353.00M | 1.48 | 1.49 | 2.03 | 3.82 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -2.41 | -4.66 | -5.40 | -4.56 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 0.36 | 0.33 | 0.27 | 0.36 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -3.31 | -3.43 | -2.65 | -2.61 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | -1.18 | -0.80 | -0.80 | -0.72 |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | -1.58 | -1.99 | -1.86 | -1.78 |
Trailing EPS (TTM)
$-0.92
Forward EPS (Est.)
$-0.62
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.45 |
| 2024-12-31 | -2.65 |
| 2023-12-31 | -3.28 |
| 2022-12-31 | -5.30 |
| 2021-12-31 | -7.16 |
| 2020-12-31 | -3.81 |
| 2019-12-31 | -1.63 |
| 2019-06-30 | -2.74 |
| 2018-06-30 | -2.86 |
| 2017-06-30 | -2.08 |
| 2016-06-30 | -1.03 |
| 2015-06-30 | -8.37 |
| 2013-08-31 | -0.03 |
| 2012-08-31 | -0.01 |
